Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guarneri

Showing results (1301-1310 of 1,433) with videos related to

Pageof 144
Sort By:
Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.
Journal of the National Cancer Institute|July 31, 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerDavide Massa, Claudio Vernieri, Lorenzo Nicolè, et al.
Expert Opinion on Biological Therapy|May 20, 2024
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database networkAndrea Spini, Giorgia Pellegrini, Ylenia Ingrasciotta, et al.
Nature Medicine|September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Parasitology|June 28, 2017
Catalase expression impairs oxidative stress-mediated signalling in Trypanosoma cruziAnna Cláudia Guimarães Freire, Ceres Luciana Alves, Grazielle Ribeiro Goes, et al.
Annals of Surgery|August 12, 2025
Beyond P Values: Novel Minimal Important Difference of the Comprehensive Complication Index (CCI®) that reflects a Meaningful Outcome for Patients Undergoing Major Abdominal SurgeryFariba Abbassi, Matthias Pfister, Julia Braun, et al.
Pageof 144

Showing results (1301-1310 of 1,433) with videos related to

Sort By:
Pageof 144
Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.
Journal of the National Cancer Institute|July 31, 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancerDavide Massa, Claudio Vernieri, Lorenzo Nicolè, et al.
Expert Opinion on Biological Therapy|May 20, 2024
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database networkAndrea Spini, Giorgia Pellegrini, Ylenia Ingrasciotta, et al.
Nature Medicine|September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Breast (Edinburgh, Scotland)|July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Parasitology|June 28, 2017
Catalase expression impairs oxidative stress-mediated signalling in Trypanosoma cruziAnna Cláudia Guimarães Freire, Ceres Luciana Alves, Grazielle Ribeiro Goes, et al.
Annals of Surgery|August 12, 2025
Beyond P Values: Novel Minimal Important Difference of the Comprehensive Complication Index (CCI®) that reflects a Meaningful Outcome for Patients Undergoing Major Abdominal SurgeryFariba Abbassi, Matthias Pfister, Julia Braun, et al.
Pageof 144